• Changes in hemoglobin and platelet levels and spleen volume compared to baseline [ Time Frame: duration of study ]
  

• Change in liver volume compared to baseline
  
• Levels of biomarkers (ACE; TRAP; CCL18; chitotriosidase; GL-1)
  
• Changes in patient-reported Quality of Life
  
• Changes in mobility, bone pain, bone crisis
  
• Changes in radiographic measures of bone disease
  

INCLUSION CRITERIA:

• The patient has a diagnosis of Gaucher Type I disease and a documented deficiency of glucocerebrosidase activity by enzyme assay and is willing and able to provide written informed consent prior to initiating any study-related procedures.
• The patient is 18 to 65 years old and weighs between 50 and 120 kg at enrollment
• The patient has the following symptoms of Gaucher disease identified within 28 days of enrollment (at Screening):
• Anemia - indicated by hemoglobin measurements taken during the screening phase
• Thrombocytopenia - indicated by platelet count measurements taken during the screening phase
• Splenomegaly, as indicated by MRI or spiral computed tomography (CT)
• Female patients of child-bearing potential must have a documented negative serum pregnancy test prior to dosing. Male and female patients agree to use a reliable method of birth control throughout duration of trial.

EXCLUSION CRITERIA:

• Patient has had a partial or total splenectomy or infarcted areas of the spleen.
• Patient has documented prior bleeding varices or liver infarction.
• Patient received miglustat within 12 months prior to study enrollment
• The patient has received an investigational product within 30 days prior to study enrollment.
• Patient has neurologic or pulmonary involvement.
• Patient has new pathological bone involvement or bone crisis in the 12 months prior to enrollment.
• Patient is transfusion-dependent.
• Patient has a documented etiology of anemia due to causes other than Gaucher disease.
• Patient has a clinically significant disease, other than Gaucher disease, including cardiovascular, renal, hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic, or psychiatric disease, other medical conditions, or serious intercurrent illnesses that, in the opinion of the Investigator, may preclude participation in the study.